Tissue-repair, gut & immune-signalling peptides
ARA-290 (Cibinetide)
Also known as cibinetide · ARA290 · pyroglutamate helix B surface peptide
An 11-amino-acid peptide from erythropoietin’s helix B that activates the "innate repair receptor" without stimulating red-cell production.
In 60 seconds
Phase 2 trials in sarcoidosis- and diabetes-associated small-fibre neuropathy; preclinical work in kidney, autoimmune and neuro models. Phase 2 studies reported it as well tolerated over the trial periods; no long-term data.
- A 28-day phase 2b randomised trial of 64 subjects measured corneal nerve fibre abundance with cibinetide.
- Describes the innate repair receptor (EPOR/CD131) and the rationale for targeting it in neuropathy.
- In a kidney ischaemia–reperfusion model, ARA290 attenuated injury without EPO’s haematopoietic effect.
Mechanism
ARA-290 targets a heteromer of the EPO receptor and the β-common receptor (CD131), switching on anti-inflammatory and tissue-protective signalling while avoiding EPO’s haematopoietic (and thrombotic) effects.
Research status
Phase 2 trials in sarcoidosis- and diabetes-associated small-fibre neuropathy; preclinical work in kidney, autoimmune and neuro models. Not approved.
Key studies
A 28-day phase 2b randomised trial of 64 subjects measured corneal nerve fibre abundance with cibinetide.
Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain — Invest Ophthalmol Vis Sci, 2017 · PMID 28475703
Describes the innate repair receptor (EPOR/CD131) and the rationale for targeting it in neuropathy.
Targeting the innate repair receptor to treat neuropathy — Pain Rep, 2016 · PMID 29392190
In a kidney ischaemia–reperfusion model, ARA290 attenuated injury without EPO’s haematopoietic effect.
ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury — J Transl Med, 2013 · PMID 23302512
A randomised human study tested whether ARA290 shares EPO’s reported effects on emotional processing.
Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action — Eur Neuropsychopharmacol, 2015 · PMID 26431906
Safety signals in the literature
Phase 2 studies reported it as well tolerated over the trial periods; no long-term data.
Legal status (South Africa)
Not registered as a medicine for human use in South Africa (unless stated otherwise); research use only.
Related compounds we stock
Now in the catalogue
ARA-290 (Cibinetide) is now in our catalogue as a research vial. Pre-orders are 10% off until the 15 October delivery lands.
Comparisons
Questions
What is ARA-290 (Cibinetide)?
An 11-amino-acid peptide from erythropoietin’s helix B that activates the "innate repair receptor" without stimulating red-cell production. ARA-290 targets a heteromer of the EPO receptor and the β-common receptor (CD131), switching on anti-inflammatory and tissue-protective signalling while avoiding EPO’s haematopoietic (and thrombotic) effects.
What is the research status of ARA-290 (Cibinetide)?
Phase 2 trials in sarcoidosis- and diabetes-associated small-fibre neuropathy; preclinical work in kidney, autoimmune and neuro models. Not approved.
What safety signals are reported for ARA-290 (Cibinetide)?
Phase 2 studies reported it as well tolerated over the trial periods; no long-term data.
Does Living Water Labs stock ARA-290 (Cibinetide)?
Not at present. ARA-290 (Cibinetide) is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Not registered as a medicine for human use in South Africa (unless stated otherwise); research use only.
More in Repair & immune
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
